4142:TPE
Adimmune Corp
16,70 TWD
arrow_upward
+0,60%(+0,10) 1 D
12. nov., 13:30:32 GMT+8 · TWD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for 4142 …
Åpne
16,55 TWD
Høy
16,90 TWD
Lav
16,55 TWD
Markedsverdi
7,17 mrd.
Snittvolum
1,14 mill.
Volum
483,07k
52 u høy
22,50 TWD
52 u lav
15,65 TWD
EPS
−0,34 TWD
Utestående aksjer
235,29 mill.
Antall ansatte
564
Åpne
16,55 TWD
Høy
16,90 TWD
Lav
16,55 TWD
Markedsverdi
7,17 mrd.
Snittvolum
1,14 mill.
Volum
483,07k
52 u høy
22,50 TWD
52 u lav
15,65 TWD
EPS
−0,34 TWD
Utestående aksjer
235,29 mill.
Antall ansatte
564
Nyhetssaker
Fra nettkilder og nyhetspartnere
Dagens Næringsliv
·
for 3 døgn siden
S&P500 slår tilbake etter børsmarerittet – endte opp over to prosent
The Globe and Mail
·
for 34 minutter siden
A $40 Million Raise Takes E-Waste Metal Recovery to the NYSE American
FTF News
·
for 44 minutter siden
Industry Players Tap the Brakes on Tokenization
Quantisnow
·
for 9 minutter siden
JP Morgan Chase & (JPM): JPMorgan notes tied to S&P 500 and Russell 2000 due November 2031
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Om Adimmune Corp
Administrerende direktør-
Ansatte564
Grunnlagt1965
Hovedkontor-
SektorHealth Care
Bransje-
Nettstedadimmune.com.tw